(Total Views: 133)
Posted On: 10/31/2023 4:49:38 PM
Post# of 90
NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Acquires Research Assets to Accelerate PAX-101 NDA Submission
PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, today announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (“RLS”). The assets were previously dedicated to the study of suramin’s potential efficacy in treating acute kidney injury resulting from chronic kidney disease. According to the announcement, the newly acquired data from RLS will play a crucial role in bolstering PaxMedica’s ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African sleeping sickness caused by the Trypanosoma brucei rhodesiense parasite. “Acquiring the research assets from Rediscovery Life Sciences marks a significant leap forward in our journey to expedite the NDA submission process for PAX-101,” said Howard Weisman, chairman and CEO of PaxMedica, in a recent statement regarding the significance of the acquisition. “This valuable addition of data will significantly contribute to our mission of delivering effective and life-saving treatments for human African sleeping sickness.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, today announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (“RLS”). The assets were previously dedicated to the study of suramin’s potential efficacy in treating acute kidney injury resulting from chronic kidney disease. According to the announcement, the newly acquired data from RLS will play a crucial role in bolstering PaxMedica’s ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African sleeping sickness caused by the Trypanosoma brucei rhodesiense parasite. “Acquiring the research assets from Rediscovery Life Sciences marks a significant leap forward in our journey to expedite the NDA submission process for PAX-101,” said Howard Weisman, chairman and CEO of PaxMedica, in a recent statement regarding the significance of the acquisition. “This valuable addition of data will significantly contribute to our mission of delivering effective and life-saving treatments for human African sleeping sickness.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
